drugset / Trial / NCT03455322
Norepinephrine Infusion Versus Midodrine & Octreotide in Patients With Hepatorenal Syndrome Type 1.
RandomizedParallel-groupSingle-blindTreatment
Summary
This study aimed to investigate the efficacy of midodrine plus octreotide versus norepinephrine and to determine the predictive factors of response in patients with HRS-AKI.
Timeline
- Start
- 2018-08-15
- Primary completion
- 2020-04-20
- Completion
- 2020-07-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Midodrine | Small molecule | 5 mg | Oral |
| Comparator | Midodrine | Small molecule | 12.5 mg | Oral |
| Comparator | Norepinephrine | Other / unclassified | 0.05 ug/kg | Intravenous |
| Comparator | Norepinephrine | Other / unclassified | 0.3 ug/kg | Intravenous |
| Comparator | Norepinephrine | Other / unclassified | 0.5 mg | Intravenous |
| Comparator | Norepinephrine | Other / unclassified | 3 mg | Intravenous |
| Comparator | Octreotide | Peptide | 100 ug | Subcutaneous |
| Comparator | Octreotide | Peptide | 200 ug | Subcutaneous |